In this episode of Medsider Radio, we had an insightful discussion with Drs. Asha Parekh and Adam Power, co-founders of Front Line Medical Technologies. The company's COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System) is a compact, minimally invasive device, designed for temporary aortic occlusion in trauma situations. 

Asha has a PhD in Biomedical Engineering from Western University, and combines technical expertise with entrepreneurial leadership. Adam is an academic and practicing vascular surgeon at Western University, with extensive training from institutions including Dalhousie, McMaster, and Mayo Clinic.

In this interview, they discuss how their clinical-engineer partnership accelerated development, their approach to clinical studies for regulatory clearance across multiple geographies, and their strategic decision to avoid VC funding during early development—and how that decision paid off.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Asha Parekh and Adam Power.

In this episode of Medsider Radio, we sat down with Kelly Huang, President and CEO of Elucid. Elucid has developed a platform that uses AI to analyze cardiac CT scans to provide a detailed, non-invasive assessment of a patient’s arterial plaque.
 
Kelly's journey spans nearly 30 years of leadership in healthcare, with expertise in driving innovation and growth across medical devices, diagnostics, health IT, and consumer health. Before Elucid, he served as COO at Cardea Bio, leading its successful acquisition by Paragraf, and as CEO of Obalon Therapeutics, where he introduced noninvasive medical devices to expand treatment options for physicians. Kelly's career also includes senior roles at L-Nutra, Nestlé/Galderma, Endo Pharmaceuticals, and Johnson & Johnson.

In this interview, Kelly shares advice on how to successfully bring novel devices to market, secure reimbursement, and drive adoption by focusing on the essentials—collaboration, trust, robust data, and transparency.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kelly Huang.

In this episode of Medsider Radio, we had an insightful chat with Nitin Salunke, President and CEO of Supira Medical, a Shifamed portfolio company. Supira is developing a catheter-based heart pump that provides hemodynamic support for patients undergoing high-risk heart procedures.

Before Supira, Nitin was Vice President of R&D at Medtronic Neurovascular, overseeing global product development. He has also held leadership roles at Altura Medical, Cordis Corp (then a Johnson & Johnson company), and W.L. Gore & Associates. Nitin holds a PhD in Mechanical Engineering and is an inventor and co-author on many patents and publications.

In this interview, Nitin shares the philosophy that guided his journey as CEO of Supira, his strategy to evaluate and address major risk factors in medtech, how to generate value for all stakeholders—patients, physicians, and investors, and his formula for creating a next-gen medical device.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Nitin Salunke.

In this episode of Medsider Radio, we sat down with Mike Dineen, co-founder and CEO of Tioga Cardiovascular, a Shifamed portfolio company. Tioga is developing a minimally invasive transcatheter mitral valve replacement (TMVR) device to address mitral regurgitation (MR) - a condition where blood flows backward into the heart, often causing heart failure.

Mike has 30 years of experience in leading and scaling innovative medical device startups, and is co-inventor on more than 65 patents. His track record encompasses leadership roles at Kalila Medical (acquired by Abbott and later divested to Terumo), Maya Medical (acquired by Covidien), and Aspire Medical (acquired by Philips/Respironics).

In this interview, Mike discusses why engaging with physicians early is essential and what he prioritizes in those conversations, the importance of pushing for early pre-clinical testing and how to best approach it, and his strategy for raising capital by targeting early-stage investors with a clear, exit-focused plan.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Mike Dineen.

In this episode of Medsider Radio, we sat down with Jennifer Fried, co-founder and CEO of Flow Medical. Her startup is developing an advanced catheter designed to treat pulmonary embolisms.

Jennifer started her career as a healthcare venture capitalist and consultant at Bain & Company. Before co-founding Flow Medical, Jennifer was the CEO and co-founder of ExplORer Surgical, a surgical software platform spun out of research at The University of Chicago. Under her leadership, ExplORer grew from an idea to a global product, earning accolades, like being named one of the Top 50 Healthcare Technology CEOs, and partnerships with major medical device companies. Jennifer successfully exited the business in 2021, when it was acquired by GHX.

In this interview, Jennifer shares insights on navigating M&As, raising capital, and tips for validating ideas. She explains why engaging early with potential acquirers is key, how challenging your assumptions can save years of effort, and the importance of tailoring your pitch and building lasting investor relationships.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Jennifer Fried.

In this episode of Medsider Radio, we sat down with Brent Ness, President and CEO of Aclarion, a startup developing a decision-support tool designed to improve the diagnosis and treatment of chronic low back pain. 

Brent has over 28 years of experience in medtech. Before Aclarion, he led Cleerly as President & CCO, driving the adoption of their AI cardiology solution through strategic partnerships. As COO of Mighty Oak Medical, he guided their FIREFLY spine navigation platform from FDA clearance to international launch. At HeartFlow, Brent spearheaded the global expansion of their image-based SaaS solution, and at Medtronic, he led the acquisition and rollout of the O-Arm technology. His career also includes leadership roles at GE Healthcare, Philips North America, and ProNerve.

In this interview, Brent shares his approach to reimbursement, why continuing to prove your technology is crucial (even after regulatory approval), and how to effectively engage with KOLs for optimal support.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Brent Ness. 

In this episode of Medsider Radio, we sat down with James Reinstein, President and CEO of Conformal Medical, a company developing a foam device that seals the left atrial appendage (LAA) to reduce the risk of stroke without anticoagulants. 

James has over 30 years of experience in the medical device industry. He’s held executive roles across multiple companies, including Saranas, Cutera, Drawbridge Health, and Aptus Endosystems (acquired by Medtronic). Earlier in his career, he served as Senior VP and Chief Commercial Officer at Cyberonics (now LivaNova) and as Vice President of Boston Scientific’s Asia region.

In this interview, James discusses choosing the right market, simplifying workflows to drive adoption, and balancing clinical focus with early commercialization planning. He also offers fundraising insights, including planning for long-term events like IPOs.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with James Reinstein. 

In this episode of Medsider Radio, we had a great chat with Rafaël Michali and Renato Circi, co-founders of SAVA, a London-based biotechnology startup developing a novel biosensing platform to monitor molecules just below the skin in real time.

Rafaël and Renato are biomedical engineers from Imperial College London. Both recognized in the Forbes 30 Under 30 list as some of Europe’s most promising young innovators in 2018, the duo raised $13M in funding and built a cross-functional team of now over 40 to develop a next-generation biosensing platform. Together, they built a thesis surrounding preventative health, from which SAVA was formed: redefining healthcare into a system that is accessible, personalized, and preventative.

In this interview, they talk about the value of identifying a large market with substantial opportunity, how they moved rapidly through development iterations, the right time to exit stealth mode, and the complexities of building a medical device.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Rafaël Michali and Renato Circi. 

In this episode of Medsider Radio, we sat down with Gabriel Sanchez, co-founder and CEO of Enspectra Health. The company's flagship VIO platform is the first FDA-cleared imaging modality for dermatology in over 25 years.

Gabriel holds a B.S. in mechanical engineering from MIT and an M.S. and Ph.D. from Stanford University, where he also served as an instructor in bioengineering and launched Enspectra to commercialize his groundbreaking research. VIO enables high-resolution, noninvasive imaging for skin cancer detection and health biometrics.

In this interview, Gabriel talks about his transition from academia to startups, how he narrowed down his idea to meet a pressing need in healthcare, the importance of speaking FDA’s language—or finding someone who does—and how he balances dilutive and non-dilutive funding.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Gabriel Sanchez. 

In this episode of Medsider Radio, we sat down with Cary Vance, CEO of PhotoniCare. The company's FDA-cleared OtoSight™ Middle Ear Scope is a clinical diagnostic tool that offers a non-invasive and comprehensive assessment of middle ear fluid.

Cary is a proven medtech leader with over two decades of experience across large strategics like GE Healthcare and Covidien, and nearly 11 years as CEO of six different startups, including Titan Medical and Hansen Medical where he drove commercialization, fundraising, and M&A opportunities. He's been the Chairman, President, and CEO of PhotoniCare since May 2023.

In this interview, Cary shares why clinical evidence, workflow efficiency, and financial viability are the three pillars of medtech success and how he prepares for launches and M&As from day one.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Cary Vance.